



SHUKRA

PHARMACEUTICALS LTD.

Date: 30th July, 2020

To,
The General Manager - Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai - 400001.

Scrip Code: 524632

Dear Sir/Madam,

Sub.:- Outcome of Board Meeting

With reference to above subject and in Compliance with the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today, i.e. 30th July, 2020 at 11:00 A.M. and concluded on 10:40 P.M. at its registered Office, inter-alia, transacted the following businesses:


- 1) Considered, approved and adopted the Audited Standalone Financial Results for the Quarter and Year ended on 31st March, 2020 along with the Auditor's Report and Certificate for unmodified opinion Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.
- 2) Reviewed the business of the company.

Please take the same on your records and oblige.

Thanking you,

Yours faithfully,

For Shukra Pharmaceuticals Limited



Arpita Shah
Company Secretary & Compliance officer

E mail :info@shukrapharmaceuticals.com | Website : http://shukrapharmaceuticals.com/

CIN : L24231GJ1993PLC019079



SHUKRA
PHARMACEUTICALS LTD.

Date: 30th July, 2020

To,
The General Manager - Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai - 400001.

Scrip Code: 524632

Dear Sir/Madam,


Sub: Declaration in respect to Audit Report with unmodified opinion for the financial year 31st March 2020

In pursuant to clause 4.1 of SEBI circular No. CIR/CFD/CMD/56/2016 dated May, 27 2016 we hereby declare that the Statutory Auditors of the Company M/s. B J Trivedi & Associates, Chartered Accountants have issued the Audit report with unmodified opinion on the standalone Financial results of the Company for the Financial Year ended on 31st March 2020 as per regulations 33(3)(d) of SEBI (LODR) Regulations, 2015.

You are requested to take note of the above.

Yours Faithfully

Shukra Pharmaceuticals Limited


Mehulkumar Patel
Chief Financial Officer

Email :info@shukrapharmaceuticals.com | Website : <http://shukrapharmaceuticals.com/>

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE' Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad-380 054.
Factory Add. 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist Gandhinagar-382721, Gujarat, India, Ph. : 02764-286317

SHUKRA PHARMACEUTICALS LIMITED

CIN: L24231GJ1993PLC019079

Reg. off address: 3rd Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road, Bodakdev, Ahmedabad Ahmedabad GJ 380003

Email id: info@shukrapharmaceuticals.com, Website: http://shukrapharmaceuticals.com/, Phone no. 02764-286317

Financial results by company

PART I		(Rs. in Lakhs)				
Statement of Standalone audited Results for the Quarter and year Ended 31/03/2020						
Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Previous year ended	
	(31/03/2020)	(31/12/2019)	(31/03/2019)	(31/03/2020)	(31/03/2019)	
(Refer Notes Below)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
I Revenue from Operation	403.58	388.03	260.51	1184.60	565.96	
II Other income	0.71	0.26	0.10	0.97	3.83	
III Total Revenue (I + II)	404.29	388.29	260.61	1185.57	569.79	
IV Expenses						
(a) Cost of materials consumed	25.46	164.68	90.26	332.82	115.62	
(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	20.61	(38.47)	(6.55)	(25.90)	(16.56)	
(d) Employee benefits expense	138.92	134.22	50.50	440.03	196.17	
(e) Finance Cost	0.14	0.00	0.04	0.21	0.06	
(f) Depreciation and amortisation expense	62.07	35.05	41.01	147.82	96.27	
(g) Other expenses	212.84	32.62	45.68	283.61	105.79	
Total expenses	460.04	328.10	220.94	1178.59	497.35	
V Profit / (Loss) before exceptional and extraordinary items and tax (III - IV)	(55.75)	60.19	39.67	6.98	72.44	
VI Exceptional items	0.20	0.00	(5.12)	0.20	0.00	
VII Profit / (Loss) before extraordinary items and tax (V - VI)	(55.95)	60.19	44.79	6.78	72.44	
VIII Extraordinary items	0.00	0.00	0.00	10.30	0.00	
IX Profit before tax (VII- VIII)	(55.95)	60.19	44.79	17.08	72.44	
X Tax expense - Provision for taxation	(16.79)	18.06	3.77	13.52	26.24	
XI Net Profit / (Loss) for the period (IX-X)	(39.17)	42.13	41.02	3.56	46.20	
XII Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	
Items that will not be reclassified to Profit or Loss: Remeasurement of defined benefits plans (net of tax)						
XIII Total Comprehensive Income) (after tax) for the period (9+10)	(39.17)	42.13	41.02	3.56	46.20	
XIV Paid up Equity Share Capital (Face value of Re. 10/- each)	156.57	156.57	156.57	156.57	156.57	
XV Other Equity excluding revaluation reserve	1361.85	1443.14	1380.99	1391.73	1380.99	
XVI Earnings per equity share:						
(1) Basic	(2.50)	2.69	2.62	0.23	2.95	
(2) Diluted	(2.50)	2.69	2.62	0.23	2.95	



Notes

The Audited Financial Results for the Quarter and Year ended 31st March, 2020, have been reviewed and recommended by the Audit Committee and

1. Approved and taken on record by the Board of Directors at their respective meetings held on 30th July, 2020. The Statutory Auditors of the Company have carried out an audit for the year ended 31st March, 2020 and the Statutory Auditors have expressed an unmodified audit opinion thereon. The Audited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to conform with the Audited Financial Statements.
2. The Audited Financial Results of the Company are available on Company's website i.e. <http://shukrapharmaceuticals.com/> and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
3. The Company is operating in single segment, so above results are for single segment only.
4. The figures of the quarter ended 31st March, 2020 are the balancing figures between Audited Figures in respect of the Full Financial year and the published year to date figures up to third quarter of the relevant financial year.
5. The management has assessed the potential impact of the COVID-19 on the Company. Based on the current assessment, the management is of the view that impact of COVID-19 on the operations of the Company and the carrying value of its assets and liabilities is not likely to be material for and up to March 31, 2020 and there has been no material change in the controls or processes followed in the closing of the financial statements and hence the necessary effects have been captured in the financial statements for the year 2019-2020.
6. Since the situation is rapidly evolving, its effect on the operations of the Company may be different from that estimated as at the date of these financial results. The Company will continue to closely monitor material changes in markets and future economic conditions.

Figures relating to the previous year / period have been regrouped / rearranged, wherever necessary, to make them comparable with those of the current year / period.

This communication is in compliance with the SEBI (Listing Obligations & Requirement) Regulations, 2015

Date : 30th July 2020

Ahmedabad

For Sukhra Pharmaceuticals Limited

Mehulkumar Patel
Chief Financial Officer



SHUKRA PHARMACEUTICALS LIMITED		
CIN: L24231GJ1993PLC019079		
Reg. off: 3rd Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road, Bodakdev, Ahmedabad Ahmedabad GJ 380003		
mail id: info@shukrapharmaceuticals.com, Website: shukrapharmaceuticals.com Phone no. 02764-286317		
Stamenet Of Assets and Liability		
(Rs. In Lacs)		
Particulars	Standalone	
	As at 31st March 2020	As at 31st March 2019
	Audited	Audited
A) Assets		
Non Current Assets		
Property Plant and Equipment	1,737.91	1,560.39
Capital Work In Progress	166.17	166.17
Other Intangible Assets		
Intangible assets under Development		
Financial Assets		
i) Investment	5.23	5.17
ii) Loan		
iii) Other Financial Assets		
Deferred Tax Assets (net)		
Other non current Assets		
Total Non Current Assets	1,909.31	1,731.73
Current Assets		
Inventories	131.87	27.07
Financial Assets		
i) Trade Receivable	795.12	534.63
ii) Cash and Cash Equivalents	12.64	24.85
iii) Bank Balance other than (ii)above		
iv) Other Financial Assets	473.88	489.11
Other Current Assets	29.93	31.64
Total Curent Assets	1,443.44	1,107.30
Total Assets	3,352.75	2,839.03
B) Equity and Liabilities		
Equity Share Capital	156.57	156.57
Other Equity	1,384.55	1,380.99
Total Equity	1,541.12	1,537.56
Non Current Liabilities		
Financial Liabilities		
i) Borrowings	805.18	605.69
Defered Tax Liabilities	309.63	296.11
Total Non Current Liabilities	1,114.81	901.80
Current Liabilities		
Financial Liabilities		
i) Borrowings		
ii) Trade Payables	644.36	314.93
iii) Other Financial Liabilities		
Provisions	52.46	84.74
Other Current Liabilities		
Total Current Liabilities	696.82	399.67
Total Equity and Liabilities	3,352.75	2,839.03

